Eversense rollout in the United States and Europe
First written in FY2022-Q2. 5 of 10 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「On 1 January 2026, the company signed an agreement to transfer the Eversense sales business to Senseonics Holdings, Inc., and the transfer of the U.S. business was completed on the same date. From the fourth quarter of the current consolidated fiscal period onward, there will be no impact on sales revenue.」
Regarding the transfer of the Eversense sales business, the transfer of the U.S. business was completed on 1 January 2026. The transfer of businesses outside the United States was scheduled for completion on 30 June 2026, with the overall process progressing in stages. - 2026-05-13AchievedEarningsSuggests it is closing out
「Under an agreement executed on 1 January 2026, the Eversense distribution business was transferred to Senseonics Holdings, Inc., and the transfer of the U.S. business was completed on the same day.」
The company moved from its previous plan to expand Eversense sales in the United States and Europe to executing an agreement to transfer the distribution business and completing the transfer of the U.S. business, indicating that the previous sales expansion initiative had reached completion. - FY2026-H1ReframedAnnual report
「On 4 September 2025 (Japan time), the company resolved at a Board of Directors meeting to enter into a basic agreement concerning the transfer of the Eversense sales business operated by its consolidated subsidiary Ascensia Diabetes Care Holdings AG (headquartered in Basel, Switzerland, hereinafter “ADCHD”) to the manufacturer, Senseonics Holdings, Inc.」
The focus shifted from expanding Eversense sales in the United States and Europe to transferring the sales business to its manufacturer, Senseonics. No business transfer agreement had been signed, and completion of the transfer was scheduled for 1 January 2026. - FY2025AdvancedAnnual report
「Revenue in the CGM business increased, mainly because Eversense 365, which can be used continuously for 1 year, was launched in the United States during the third quarter of the current consolidated fiscal period.」
Eversense 365 was launched in the United States, and the rollout of a product that can be used continuously for 1 year contributed to higher revenue in the CGM business. - FY2024RestatedAnnual report
「Since launching the six-month Eversense E3 in the United States and Europe in 2022, the number of users has increased substantially, establishing the system as a foundation for significant growth.」
The company reaffirmed the rollout of Eversense E3 in the United States and Europe and its establishment as a growth platform. Meanwhile, for the full year, user growth in the CGM business fell below expectations and revenue growth was limited. - FY2023-Q3RestatedAnnual report
「Revenue from continuous glucose monitoring devices (CGM) increased following the first-quarter launch of Senseonics' implantable CGM, EversenseE3, in the U.S. market.」
The company reaffirmed that Eversense E3, which has already launched in the United States, contributed to higher CGM sales revenue. - FY2023-Q2AdvancedAnnual report
「Revenue from continuous glucose monitoring devices (CGM) increased following the first-quarter launch of Senseonics' implantable CGM, Eversense E3, in the U.S. market.」
It stated that Eversense E3, launched in the United States, contributed to higher CGM sales revenue after its launch. - FY2023-Q1AdvancedAnnual report
「The company also began selling Eversense E3 (manufactured by Senseonics), an implantable continuous glucose monitoring (CGM) product that can be used continuously for 180 days, in the United States.」
The company described the launch of Eversense E3 in the United States as a new stage in its rollout. - FY2022-Q3AdvancedAnnual report
「The world's first implantable CGM product, Eversense (manufactured by Senseonics), launched in the United States and 8 European countries in April 2021, recorded higher sales in the third quarter.」
It was stated that Eversense sales increased in the third quarter after the product was launched in the United States and 8 European countries. - FY2022-Q2First statedAnnual report
「In April 2021, the company began exclusive sales of the world's first implantable CGM product, Eversense (manufactured by Senseonics), in the United States and 8 European countries. Sales of the product in the United States fell below plan, but sales in Europe exceeded plan, enabling the business to achieve its sales revenue plan for the current period.」
Exclusive sales began in the United States and 8 European countries in April 2021, with the variance from plan explained by region.